Expert Opinion on Drug Safety, Volume 18, Issue 7 (2019)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Drug Safety, Volume 18, Issue 7 (2019)

See all volumes and issues
Vol 23, 2024 Vol 22, 2023 Vol 21, 2022 Vol 20, 2021 Vol 19, 2020 Volume 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Vol 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002
Download citations Download PDFs Download issue

Editorial

Editorial
Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Nicholas T. Bello
Pages: 549-552
Published online: 17 May 2019
First Page PreviewforUpdate on drug safety evaluation of naltrexone/bupropion for the treatment of obesity | Full Text | References | PDF (382.2 KB) | EPUB
  • 7807 Views
  • 5 CrossRef citations
  • 0Altmetric
Free Access

Drug Evaluation

Article
Benefits versus risk profile of buparlisib for the treatment of breast cancer
Anne Patsouris, Paule Augereau, Jean-Sebastien Frenel, Marie Robert, Carole Gourmelon, Emmanuelle Bourbouloux, Dominque Berton-Rigaud, Louise-Marie Chevalier & Mario Campone
Pages: 553-562
Published online: 17 Jun 2019
AbstractforBenefits versus risk profile of buparlisib for the treatment of breast cancer | Full Text | References | PDF (785.4 KB) | EPUB
  • 297 Views
  • 7 CrossRef citations
  • 0Altmetric

Review

Review
A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma
Guldane Cengiz Seval & Meral Beksac
Pages: 563-571
Published online: 09 May 2019
AbstractforA comparative safety review of histone deacetylase inhibitors for the treatment of myeloma | Full Text | References | PDF (716.4 KB) | EPUB
  • 468 Views
  • 23 CrossRef citations
  • 0Altmetric
Review
Muscle and statins: from toxicity to the nocebo effect
Juan Pedro-Botet, Elisenda Climent & David Benaiges
Pages: 573-579
Published online: 09 May 2019
AbstractforMuscle and statins: from toxicity to the nocebo effect | Full Text | References | PDF (688.6 KB) | EPUB
  • 654 Views
  • 27 CrossRef citations
  • 0Altmetric
Review
An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis
Mariana Luís, João Freitas, Flávio Costa, Frank Buttgereit, Maarten Boers, Da Silva JAP & Tânia Santiago
Pages: 581-590
Published online: 14 May 2019
AbstractforAn updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis | Full Text | References | PDF (982.5 KB) | EPUB
  • 637 Views
  • 26 CrossRef citations
  • 0Altmetric
Review
Safety of epidural drugs: a narrative review
ML van Zuylen, W ten Hoope, EME Bos, J Hermanides, MF Stevens & MW Hollmann
Pages: 591-601
Published online: 20 May 2019
AbstractforSafety of epidural drugs: a narrative review | Full Text | References | PDF (1,018.3 KB) | EPUB
  • 6116 Views
  • 8 CrossRef citations
  • 0Altmetric
Open Access
Review
Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis
Giovanni Galati, Moises Muley, Mauro Viganò, Massimo Iavarone, Alessandro Vitale, Chiara Dell’Unto, Quirino Lai, Giuseppe Cabibbo, Rodolfo Sacco, Erica Villa & Franco Trevisani
Pages: 603-610
Published online: 20 May 2019
AbstractforOccurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis | Full Text | References | PDF (950.6 KB) | EPUB
  • 305 Views
  • 11 CrossRef citations
  • 0Altmetric
Review
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Larysa Strilchuk, Federica Fogacci & Arrigo Fg Cicero
Pages: 611-621
Published online: 29 May 2019
AbstractforSafety and tolerability of injectable lipid-lowering drugs: an update of clinical data | Full Text | References | PDF (1 MB) | EPUB
  • 616 Views
  • 33 CrossRef citations
  • 0Altmetric

Original Research

Article
Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system
Pushkar Aggarwal
Pages: 623-633
Published online: 22 May 2019
AbstractforDisproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system | Full Text | References | PDF (888.6 KB) | EPUB
  • 479 Views
  • 19 CrossRef citations
  • 0Altmetric

Explore articles